US 12054718
RNAi agents for inhibiting expression of PNPLA3, pharmaceutical compositions thereof, and methods of use
granted A61KA61K31/713A61K45/06
Quick answer
US patent 12054718 (RNAi agents for inhibiting expression of PNPLA3, pharmaceutical compositions thereof, and methods of use) held by Arrowhead Pharmaceuticals, Inc. expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Arrowhead Pharmaceuticals, Inc.
- Grant date
- Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 34
- CPC classes
- A61K, A61K31/713, A61K45/06, A61K47/549, A61P